Literature DB >> 19159938

[Leflunomide in combination with TNF-blockers for Methotrexate intolerance].

K Krüger1, B Manger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19159938     DOI： 10.1007/s00393-008-0422-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  14 in total

1.  Effectiveness and safety of infliximab combined with leflunomide in chronic polyarthritis.

Authors:  A M Ortiz García; I González-Alvaro; R Roselló Pardo; L Carmona; M D Fábregas Canales; I Monteagudo Saez
Journal:  Clin Exp Rheumatol       Date:  2004 Nov-Dec       Impact factor: 4.473

2.  Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis.

Authors:  T Cobo Ibáñez; M Yehia Tayel; A Balsa Criado; A Hernández Sanz; E Martín Mola
Journal:  Rheumatology (Oxford)       Date:  2005-09-20       Impact factor: 7.580

3.  Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.

Authors:  D C Nordström; L Konttinen; M Korpela; T Tiippana-Kinnunen; K Eklund; S Forsberg; K Ilva; O Kaipiainen-Seppänen; T Malmi; T Ylä-Kerttula; V Honkanen
Journal:  Rheumatol Int       Date:  2005-10-05       Impact factor: 2.631

4.  Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs.

Authors:  A Maetzel; A Wong; V Strand; P Tugwell; G Wells; C Bombardier
Journal:  Rheumatology (Oxford)       Date:  2000-09       Impact factor: 7.580

5.  Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.

Authors:  Gerd R Burmester; Xavier Mariette; Carlomaurizio Montecucco; Indalecio Monteagudo-Sáez; Michel Malaise; Athanasios G Tzioufas; Johannes W J Bijlsma; Kristina Unnebrink; Sonja Kary; Hartmut Kupper
Journal:  Ann Rheum Dis       Date:  2007-02-28       Impact factor: 19.103

6.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

7.  Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice.

Authors:  Aleth Perdriger; Xavier Mariette; Jean-Louis Kuntz; Olivier Brocq; Rym Kara-Terki; Xavier Le Loet; Alain Cantagrel; Stephan Pavy; Chantal Job Deslandre; Françoise Debiais; Bernard Combe
Journal:  J Rheumatol       Date:  2006-05       Impact factor: 4.666

Review 8.  Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis.

Authors:  Joachim R Kalden; Christian Antoni; Jose M Alvaro-Gracia; Bernard Combe; Paul Emery; Joel M Kremer; C Vibeke Strand; Piet Van Riel; Josef S Smolen
Journal:  J Rheumatol       Date:  2005-08       Impact factor: 4.666

9.  Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.

Authors:  Grant W Cannon; William L Holden; Juhaeri Juhaeri; Wanju Dai; Linda Scarazzini; Paul Stang
Journal:  J Rheumatol       Date:  2004-10       Impact factor: 4.666

10.  Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

Authors:  Daniel E Furst; Michael H Schiff; Roy M Fleischmann; Vibeke Strand; Charles A Birbara; Daniele Compagnone; Steven A Fischkoff; Elliot K Chartash
Journal:  J Rheumatol       Date:  2003-12       Impact factor: 4.666
View more
  2 in total

1.  [Leflunomide and TNF inhibitors. Experiences from precription recourse proceedings].

Authors:  J Brandt-Jürgens
Journal:  Z Rheumatol       Date:  2013-03       Impact factor: 1.372

Review 2.  [Off-label therapy of rheumatoid arthritis and spondyloarthritis].

Authors:  K Krüger; J Sieper
Journal:  Z Rheumatol       Date:  2012-02       Impact factor: 1.372
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.